Publications

Our periodic publications on vitiligo are now attracting attention from public, regulatory bodies, industry, advocacy groups, and the academic research community.

LIFESTYLE

  • ABC's Of Vitiligo (coming soon)
  • Newly Diagnosed: First Steps (coming soon)
  • Vitiligo Q&A is available now in Chinese, Croatian, English, Italian, Macedonian and Russian 

CLINIC

RESEARCH

NEW! Sodium oxodihydroacridinylacetate for treatment of an active vitiligo. Abstract and Presentation at the EADV (24 May 2013)

Dermatologic Therapy Journal (December 2012) "Vitiligo: State Of The Art"

Dermatologic TherapyA global interest in therapies for neglected diseases is rising, but traditional biopharma research and development process is prohibitively expensive to justify cost of their development. Vitiligo is a multifactorial orphan disease that affects at minimum 35 million people worldwide, yet no therapeutic solutions exist. We describe a budget-minded pursuit of the new therapy development for vitiligo, which includes a multidiscipline collaboration and effective bridging between academic research, biobanking, and bioinformatics. We anticipate that the our “theoretically induced and empirically guided” discovery process will enable development of more leads, with a much greater probability of success and under tighter budgets compared with those of the biopharma company. Ultimately, the multidisciplinary approach described below facilitates the collaborative development of personalized treatments for different patient subpopulations in vitiligo and other neglected diseases.

.

The following works and publications have been supported with grants from the VR Foundation:

  • Valle Y., Couture P., Lotti T., Korobko I. Cloud Medical Research Management (MRM): a Bio-IT tool for correlative studies in dermatology. (Journal Link, pdf) Treat Strategies (Dermatol). 2011; 1(1): 82-86.
  • Minashkin MM, Salnikova LE, Lomonosov KM, Korobko IV, Tatarenko AO
    Possible contribution of GSTP1 and other xenobiotic metabolizing genes to vitiligo susceptibility (Abstract)
  • Lotti T., Hercogova J., Turini D., Tognetti L., Barygina V., Valle Y. (Eds). Natural Antioxidants in General Medicine and in Dermatology. World Health Academy Publication House (Zurich, CH), 2011. (Amazon link)
  • Zhou L., Li K., Shi Y.-L., Hamzavi I., Gao T.-W., Henderson M., Huggins R. H., Agbai O., Mahmoud B., Mi X., Lim H. W., Mi Q.-S. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T-cells. Pigment Cell Melanoma Res. 2012; 25(5): 602-611 (Abstract)
  • Babeshko O.A., Lomonosov K.M., Gilyadova N.I. Role of cytokine in vitiligo pathogenesis. Russ J Skin Sex Transm Dis. 2012, (3): 37-41.
  • Lomonosov K.M., Mironov A.Yu., Kuznetsov O.V., Babeshko O.A. Virus participation in vitiligo pathogenesis. Russ J Skin Sex Transm Dis. 2012; (1): 40-42.
  • Lomonosov K.M., Esipov D.S., Babeshko O.A., Tatarenko A.O. Oxidative stress in pathogenesis of vitiligo. (Journal Link) Russ J Skin Sex Transm Dis. 2011; (1): 68-70.

Periodic Research Reviews

Newly diagnosed

Get email alerts about the latest treatments, research advances, and opportunities to get involved.

ABC's Of Vitiligo
living with vitiligo Join our community DONATE TODAY
image description

I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.

SIGN PETITION

FAQ

Copyright (c) 2011-2013 VR Foundation, Inc. All rights reserved. VR FoundationTM, and the 'VR Foundation' logo, are trademarks of VR Foundation, Inc.